| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 6.02▲ | 6.02▲ | 6.02▲ | 6.05▲ | 6.04▲ |
| MA10 | 5.96▲ | 5.95▲ | 5.94▲ | 5.87▲ | 5.98▲ |
| MA20 | 5.89▲ | 5.88▲ | 5.85▲ | 5.81▲ | 6.02▲ |
| MA50 | 5.97▲ | 5.97▲ | 5.96▲ | 5.91▲ | N/A |
| MA100 | 6.07▲ | 6.29▲ | 6.34▲ | 6.27▲ | N/A |
| MA200 | N/A | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | N/A | N/A | N/A | N/A | N/A |
| RSI | N/A | N/A | N/A | N/A | N/A |
| STOCH | 62.081 | 68.103 | 77.037 | 62.625 | 49.691 |
| WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -36.253 | -30.781 |
| CCI | 403.571▲ | 405.914▲ | 389.461▲ | 456.101▲ | 176.775▲ |
|
Wednesday, September 18, 2019 05:00 AM
HOUSTON, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) today announced that its late-breaking abstract has been accepted for oral presentation in a proffered paper session at the ...
|
|
Tuesday, August 13, 2019 01:00 AM
About Aravive Aravive, Inc. (Nasdaq: ARAV) is a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and ...
|
|
Thursday, August 08, 2019 01:16 PM
August 08, 2019 16:15 ET | Source: Aravive, Inc. HOUSTON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 18/09/19 | 5.84 | 7.776 | 5.836 | 6.94 | 164,300 |
| 17/09/19 | 5.75 | 5.96 | 5.75 | 5.92 | 7,500 |
| 16/09/19 | 5.67 | 5.99 | 5.67 | 5.85 | 43,500 |
| 13/09/19 | 5.77 | 5.975 | 5.73 | 5.78 | 20,600 |
| 12/09/19 | 5.68 | 5.97 | 5.68 | 5.77 | 19,400 |
| 11/09/19 | 5.65 | 6.00 | 5.65 | 5.80 | 32,500 |
| 10/09/19 | 5.69 | 5.85 | 5.60 | 5.665 | 47,900 |
| 09/09/19 | 5.70 | 5.90 | 5.59 | 5.648 | 13,800 |
| 06/09/19 | 5.57 | 5.90 | 5.57 | 5.70 | 7,600 |
| 05/09/19 | 5.89 | 5.89 | 5.5511 | 5.60 | 2,422 |
|
|
||||
|
|
||||
|
|